CHFR: A novel mitotic checkpoint protein and regulator of tumorigenesis

Translational Oncology

Volumn 1, Issue 2, 2008, Pages 57-64

  Privette, Lisa M ^a   Petty, Elizabeth M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149329306     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.08109     Document Type: Article

References (64)

1. Scolnick DM and Halazonetis TD (2000). Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406, 430-435.
2. Daniels MJ, Marson A, and Venkitaraman AR (2004). PML bodies control the nuclear dynamics and function of the CHFR mitotic checkpoint protein. Nat Struct Mol Biol 11, 1114-1121.
3. Fukuda T, Kondo Y, and Nakagama H (2008). The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by RING finger domain. PLoS ONE 3, e1776.
4. Bothos J, Summers MK, Venere M, Scolnick DM, and Halazonetis TD (2003). The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene 22, 7101-7107.
5. 2 to M transition. J Cell Biol 156, 249-259.
6. Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, and Zhou BB (2002). Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 62, 1797-1801.
7. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J, et al. (2005). Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 37, 401-406.
8. Ahel I, Ahel D, Matsusaka T, Clark AJ, Pines J, Boulton SJ, and West SC (2008). Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451, 81-85.
9. Fraschini R, Bilotta D, Lucchini G, and Piatti S (2004). Functional characterization of Dma1 and Dma2, the budding yeast homologues of Schizosaccharomyces pombe Dma1 and human Chfr. Mol Biol Cell 15, 3796-3810.
10. Guertin DA, Venkatram S, Gould KL, and McCollum D (2002). Dma1 prevents mitotic exit and cytokinesis by inhibiting the septation initiation network (SIN). Dev Cell 3, 779-790.
11. Murone M and Simanis V (1996). The fission yeast dma1 gene is a component of the spindle assembly checkpoint, required to prevent septum formation and premature exit from mitosis if spindle function is compromised. EMBO J 15, 6605-6616.
12. Plans V, Guerra-Rebollo M, and Thomson TM (2008). Regulation of mitotic exit by the RNF8 ubiquitin ligase. Oncogene 27, 1355-1365.
13. Huen MS, Grant R, Manke I, Minn K, Yu X, Yaffe MB, and Chen J (2007). RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131, 901-914.
14. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, and Lukas J (2007). RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131, 887-900.
15. Shtivelman E (2003). Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR. Mol Cancer Res 1, 959-969.
16. Summers MK, Bothos J, and Halazonetis TD (2005). The CHFR mitotic checkpoint protein delays cell cycle progression by excluding cyclin B1 from the nucleus. Oncogene 24, 2589-2598.
17. Ogi K, Toyota M, Mita H, Satoh A, Kashima L, Sasaki Y, Suzuki H, Akino K, Nishikawa N, Noguchi M, et al. (2005). Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 4, 773-780.
18. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, et al. (2003). Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63, 8606-8613.
19. Privette LM, Gonzalez ME, Ding L, Kleer CG, and Petty EM (2007). Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res 67, 6064-6074.
20. 2/M checkpoint defects in breast cancer cells. Mol Carcinog 39, 26-33.
21. Matsusaka T and Pines J (2004). Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells. J Cell Biol 166, 507-516.
22. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H, and Oshimura M (2007). SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 26, 945-957.
23. Akhter S, Richie CT, Deng JM, Brey E, Zhang X, Patrick C Jr, Behringer RR, and Legerski RJ (2004). Deficiency in SNM1 abolishes an early mitotic checkpoint induced by spindle stress. Mol Cell Biol 24, 10448-10455.
24. Privette LM, Weier JF, Nguyen HN, Yu X, and Petty EM (2008). Loss of CHFR expression in mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia 10, 643-652.
25. Michael S, Trave G, Ramu C, Chica C, and Gibson TJ (2008). Discovery of candidate KEN box motifs using cell cycle keyword enrichment combined with native disorder prediction and motif conservation. Bioinformatics 24, 453-457.
26. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, and Saya H (2003). Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114, 585-598.
27. Oh YM, Yoo SJ, and Seol JH (2007). Deubiquitination of Chfr, a checkpoint protein, by USP7/HAUSP regulates its stability and activity. Biochem Biophys Res Commun 357, 615-619.
28. Bertholon J, Wang Q, Falette N, Verny C, Auclair J, Chassot C, Navarro C, Saurin JC, and Puisieux A (2003). Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene 22, 8956-8960.
29. Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnik DM, Kittas C, Halazonetis TD, and Gorgoulis VG (2003). Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res 63, 7185-7189.
30. Kang HC, Kim IJ, Jang SG, Hong SH, Hwang JA, Shin HR, and Park JG (2008). Coding region polymorphisms in the CHFR mitotic stress checkpoint gene are associated with colorectal cancer risk. Cancer Lett 260, 170-179.
31. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, et al. (2003). Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 100, 7818-7823.
32. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, et al. (2006). Array CGH profiling of favourable histology Wilms tumors reveals novel gains and losses associated with relapse. J Pathol 210, 49-58.
33. Rickert CH, Dockhorn-Dworniczak B, Busch G, Moskopp D, Albert FK, Rama B, and Paulus W (2001). Increased chromosomal imbalances in recurrent pituitary adenomas. Acta Neuropathol 102, 615-620.
34. Rutherford S, Hampton GM, Frierson HF, and Moskaluk CA (2005). Mapping of candidate tumor suppressor genes on chromosome 12 in adenoid cystic carcinoma. Lab Invest 85, 1076-1085.
35. Aubele M, Auer G, Braselmann H, Nahrig J, Zitzelsberger H, Quintanilla-Martinez L, Smida J, Walch A, Hofler H, and Werner M (2002). Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol 24, 77-87.
36. Ichikawa T, Hosoki S, Suzuki H, Akakura K, Igarashi T, Furuya Y, Oshimura M, Rinker-Schaeffer CW, Nihei N, Barrett JC, et al. (2000). Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer. Asian J Androl 2, 167-171.
37. Jaeger EB, Chekmareva MA, Tennant TR, Luu HH, Hickson JA, Chen SL, Samant RS, Sokoloff MH, and Rinker-Schaeffer CW (2004). Inhibition of prostate cancer metastatic colonization by approximately 4.2 Mb of human chromosome 12. Int J Cancer 108, 15-22.
38. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, et al. (2007). Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol 31, 713-720.
39. Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, and Herman JG (2005). CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26, 1152-1156.
40. Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, Sethi S, Stephen JK, and Worsham MJ (2007). Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 133, 1131-1138.
41. Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung A, Tsao SW, Wang Q, Yeun PW, et al. (2005). Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol Carcinog 43, 237-245.
42. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, and El-Deiry WS (2003). Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24, 47-51.
43. Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG, Weijenberg MP, de Bruine AP, Meijer GA, and van Engeland M (2008). Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 29, 434-439.
44. Gong H, Liu W, Zhou J, and Xu H (2005). Methylation of gene CHFR promoter in acute leukemia cells. J Huazhong Univ Sci Technolog Med Sci 25, 240-242.
45. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, Schouten JP, Meijer CJ, Snijders PJ, and Steenbergen RD (2007). Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 97, 1457-1464.
46. Homma N, Tamura G, Honda T, Jin Z, Ohmura K, Kawata S, and Motoyama T (2005). Hypermethylation of Chfr and hMLH1 in gastric noninvasive and early invasive neoplasias. Virchows Arch 446, 120-126.
47. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S, and Motoyama T (2004). Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer 90, 2013-2016.
48. Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, Campan M, and Laird PW (2008). DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88, 161-170.
49. Kang HC, Kim IJ, Park JH, Shin Y, Park HW, Ku JL, Yang HK, Lee KU, Choe KJ, and Park JG (2004). Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Oncol Rep 12, 129-133.
50. Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, and Ogino S (2008). CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol 21, 245-255.
51. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, and Miyazaki K (2006). The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 41, 133-139.
52. Ludwig AH, Bujko M, Bidzinski M, and Kupryjanczyk J (2007). CHFR gene is neither mutated nor hypermethylated in ovarian cancer. Cancer Detect Prev 31, 257-261.
53. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, and Takahashi T (2002). Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21, 2328-2333.
54. Morioka Y, Hibi K, Sakai M, Koike M, Fujiwara M, Kodera Y, Ito K, and Nakao A (2006). Aberrant methylation of the CHFR gene is frequently detected in noninvasive colorectal cancer. Anticancer Res 26, 4267-4270.
55. Morioka Y, Hibi K, Sakai M, Koike M, Fujiwara M, Kodera Y, Ito K, and Nakao A (2006). Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res 26, 1791-1795.
56. Sakai M, Hibi K, Kanazumi N, Nomoto S, Inoue S, Takeda S, and Nakao A (2005). Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Hepatogastroenterology 52, 1854-1857.
57. Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, et al. (2002). Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 23, 1695-1699.
58. Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, Kojima A, Egashira A, Morita M, Kakeji Y, et al. (2006). Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Res Treat 97, 199-203.
59. Tozawa T, Tamura G, Honda T, Nawata S, Kimura W, Makino N, Kawata S, Sugai T, Suto T, and Motoyama T (2004). Promoter hypermethylation of DAPkinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 95, 736-740.
60. van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, et al. (2005). Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23, 3886-3896.
61. Yanokura M, Banno K, Kawaguchi M, Hirao N, Hirasawa A, Susumu N, Tsukazaki K, and Aoki D (2007). Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol Rep 17, 41-48.
62. Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, and Yasui W (2006). DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Anticancer Res 26, 49-54.
63. Milne AN, Sitarz R, Carvalho R, Polak MM, Ligtenberg M, Pauwels P, Offerhaus GJ, and Weterman MA (2007). Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis. Hum Pathol 38, 903-913.
64. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, and Tsuneyoshi M (2006). Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol 19, 524-532.